Active, not recruitingPhase 2NCT05215470

CLARA: Somatic and Germline Mechanisms That Impact Renal Cancer Immunotherapy

Studying MiT family translocation renal cell carcinoma

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Hospital das Clínicas de Ribeirão Preto
Principal Investigator
Leandro Machado Colli, MD, PhD
University of Sao Paulo
Intervention
Nivolumab(drug)
Enrollment
100 enrolled
Eligibility
18 years · All sexes
Timeline
20222026

Study locations (1)

Collaborators

Bristol-Myers Squibb · Fundação de Amparo à Pesquisa do Estado de São Paulo

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT05215470 on ClinicalTrials.gov

Other trials for MiT family translocation renal cell carcinoma

Additional recruiting or active studies for the same condition.

See all trials for MiT family translocation renal cell carcinoma

← Back to all trials